---
title: "3 Different Ways to Play the Rally in Psychedelic Stocks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284035619.md"
description: "The recent surge in interest in psychedelic stocks is linked to President Trump's executive order aimed at enhancing research and access to drugs like psilocybin and MDMA for treating mental illnesses. However, investing in these stocks carries risks due to their small market caps and low trading volumes, which can lead to wider spreads and potential profitability issues. The popularity of these stocks may also be fleeting, reminiscent of the decline seen in marijuana stocks, as exemplified by Tilray Brands' significant loss in value over the past five years."
datetime: "2026-04-24T16:22:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284035619.md)
  - [en](https://longbridge.com/en/news/284035619.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284035619.md)
---

# 3 Different Ways to Play the Rally in Psychedelic Stocks

I'm getting a lot of questions about psychedelic stocks. The public suddenly achieved mass awareness about the existence of these stocks over the past week.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

This expanded consciousness can be attributed to President Trump's executive order, signed last week, to accelerate research and improve access to drugs like psilocybin and MDMA. The hope is that these drugs will eventually be used as unconventional treatments for serious mental illnesses.

## **Warning Label**

Be forewarned. Like the drugs themselves, experimenting with psychedelic stocks can be dangerous. Many of these companies have small market caps and trade on minimal volume. This leads to wider spreads, which can become an obstacle to profitability.

There is also a chance that the popularity of these stocks could be transitory. That's what happened with marijuana stocks — an initial flurry of activity, followed by a long, slow decline.

Shareholders of names like Tilray Brands (TLRY) know firsthand the damage that can occur. Shares of the consumer cannabis company have lost 95% of their value over the past five years.

### Related Stocks

- [PSIL.US](https://longbridge.com/en/quote/PSIL.US.md)
- [TLRY.US](https://longbridge.com/en/quote/TLRY.US.md)

## Related News & Research

- [Trump's psychedelic drug order boosts investor interest with promise of faster reviews](https://longbridge.com/en/news/286750347.md)
- [10:15 ETLEVEL Sleep Protab Improved Sleep Quality and Next-Morning Outcomes in Independent 29-Day Study](https://longbridge.com/en/news/287236615.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)
- [Some May Be Optimistic About ICL Group's (NYSE:ICL) Earnings](https://longbridge.com/en/news/287063804.md)